Bicalutamide: Side Effects, Uses & Monitoring
Facts extracted from current FDA product labeling for Bicalutamide. Educational only — not medical advice.
Labeled uses
Bicalutamide tablets, USP 50 mg daily are indicated for use in combination therapy with a luteinizing hormone-releasing hormone (LHRH) analog for the treatment of Stage D2 metastatic carcinoma of the prostate. Bicalutamide tablets, USP 150 mg daily are not approved for use alone or with other treatments [see Clinical Studies (14.2)].
Source: FDA labeling via NIH DailyMed (set 10e21544…). Not affiliated with FDA or NIH.
Medical disclaimer: Always consult a qualified healthcare professional about any medication.